Positions
- Professor
-
Breast Center; Department of Molecular & Cellular Biology; Department of Molecular Virology & Microbiology
Baylor College of Medicine
Houston, TX, US
- Member
-
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States
- Faculty Senator
-
Baylor College of Medicine
Houston, Texas, United States
- Member
-
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Addresses
- BCM-Alkek Graduate School (Lab)
-
Mail Stop: BCM600
Houston, TX, 77030
United States
Phone: (713) 798-3963
liyi@bcm.edu
- BCM-Alkek Graduate School (Office)
-
Mail Stop: BCM600
Houston, TX, 77030
United States
Phone: (713) 798-3963
liyi@bcm.edu
Education
- BS from Jiangsu Agricultural College
- 07/1984 - Yangzhou, Jiangsu, China, People's Rep
- MS from Jiangsu Agricultural College
- 07/1987 - Yangzhou, Jiangsu, China, People's Rep
- PhD from Michigan State University
- 01/1996 - East Lansing, Michigan, United States
- Postdoctoral Training at National Cancer Institute
- 01/2000 - Bethesda, Maryland, United States
- Postdoctoral Training at Memorial Sloan Kettering Cancer Center
- 10/2002 - New York, New York, United States
Professional Interests
- Mouse and rat models of breast cancer
- Immune cells and breast cancer metastasis and therapy
- JAK-STAT and Bcl-xL signaling breast cancer
Professional Statement
The Li lab has developed multiple novel mouse and rat models that closely mimic human breast cancer initiation and progression. Using these models and cell biological, biochemical, genetic, and omic approaches, they have gained insights into Wnt-EGFR signaling in cancer progression, and discovered a JAK2-STAT5-regulated anti-apoptosis mechanism in promoting breast cancer development. Furthermore, their preclinical work on intermittent anti-JAK treatment for preventing breast cancer has resulted in a multi-center window-of-opportunity clinical trial (TBCRC042). Their recent success in introducing oncogenic drivers directly into mammary cells in rats has led to first models that can fully mimic human ER+ breast cancer. They are now utilizing these models to study how ER+ breast tumors metastasize and develop resistance to cancer therapies.
Selected Publications
-
Du Z, Podsypanina K, Huang S, McGrath A, Toneff MJ, Bogoslovskaia E, Zhang X, Moraes RC, Fluck M, Allred DC, Lewis MT, Varmus HE, Li Y.. " Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models " Proc Natl Acad Sci USA.. 2006 Nov ; 103 (46) : 17396-401.
Pubmed PMID: 17090666. -
32) Reddy, J.P., Peddibhotla, S., Bu, W., Zhao, J., Haricharan, S., Du, Y.C., Podsypanina, K., Rosen, J.M., Donehower, L.A. and Li, Y. " Defining the ATM-mediated barrier to tumorigenesis in somatic mammary cells following ErbB2 activation " PNAS. 2010 ; 107 (8) : 3728-33.
Pubmed PMID: 20133707. -
Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G.. " p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer " Cancer Cell.. 2012 Jun ; 21 : 793-806.
Pubmed PMID: 22698404. -
Haricharan S, Hein SM, Dong J, Toneff MJ, Aina OH, Rao PH, Cardiff RD, Li Y.. " Contribution of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancer. " Oncogene.. 2013 Dec 9;
Pubmed PMID: 24317513.
Log In to edit your profile